Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Trial Profile

Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms S-TRAC; S-TRAC
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Feb 2018 According to a Pfizer media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against expanding use of SUTENT (sunitinib) to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).
    • 10 Feb 2018 Results of exploratory pharmacogenomic analysis presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 Results assessing efficacy and tolerability of adjuvant sunitinib in patients with renal cell carcinoma with a high risk of recurrence, were presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top